Barinthus Biotherapeutics (BRNS) Institutional Ownership $1.00 -0.06 (-5.21%) Closing price 02/21/2025 04:00 PM EasternExtended Trading$1.06 +0.06 (+5.60%) As of 02/21/2025 07:50 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Ownership Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesOwnershipSEC FilingsShort InterestTrends Institutional Ownership Changes (13F Filings) for Barinthus Biotherapeutics (NASDAQ:BRNS)CurrentInstitutional OwnershipPercentage25.20%Number ofInstitutional Buyers(last 12 months)7TotalInstitutional Inflows(last 12 months)$13.02MNumber ofInstitutional Sellers(last 12 months)0 Get BRNS Insider Trade Alerts Want to know when executives and insiders are buying or selling Barinthus Biotherapeutics stock? Sign up for InsiderTrades.com's daily newsletter to get the latest insider transactions delivered to your inbox daily. Email Address Skip Chart & View Institutional Buying and Selling Data BRNS Institutional Buying and Selling by Quarter Barinthus Biotherapeutics Major Shareholders & Ownership History Export to ExcelReporting DateMajor Shareholder NameShares HeldMarket Value% of PortfolioQuarterly Change in SharesOwnership in CompanyDetails2/14/2025 Gilead Sciences Inc.620,351$749K0.0%N/A1.542% 8/2/2024 Alphabet Inc.1,513,644$2.12M0.1%N/A3.878% 7/24/2024 Catalina Capital Group LLC17,819$25K0.0%N/A0.046% 7/16/2024 Ipswich Investment Management Co. Inc.23,075$32K0.0%N/A0.059% 7/16/2024 M&G Plc5,197,349$7.28M0.0%N/A13.316% 5/16/2024 BlueCrest Capital Management Ltd542,673$1.29M0.1%N/A1.394% 5/14/2024 DC Funds LP642,204$1.53M14.8%N/A1.650% (Data available from 1/1/2016 forward) BRNS Institutional Ownership - Frequently Asked Questions Who are the largest shareholders of BRNS shares? During the previous two years, the following institutional investors and hedge funds held shares of Barinthus Biotherapeutics shares: M&G Plc ($7.28M), Alphabet Inc. ($2.12M), DC Funds LP ($1.53M), BlueCrest Capital Management Ltd ($1.29M), Gilead Sciences Inc. ($749K), and Ipswich Investment Management Co. Inc. ($32K), and Catalina Capital Group LLC ($25K).Learn more on BRNS's institutional investors. What percentage of Barinthus Biotherapeutics stock is owned by institutional investors? 25.20% of Barinthus Biotherapeutics stock is owned by institutional investors. Learn more on BRNS's institutional investor holdings. Which institutional investors have been buying Barinthus Biotherapeutics stock? The following institutional investors have purchased Barinthus Biotherapeutics stock in the last 24 months: M&G Plc ($5.20M), Alphabet Inc. ($1.51M), DC Funds LP ($642.20K), Gilead Sciences Inc. ($620.35K), BlueCrest Capital Management Ltd ($542.67K), Ipswich Investment Management Co. Inc. ($23.08K), and Catalina Capital Group LLC ($17.82K). How much institutional buying is happening at Barinthus Biotherapeutics? Institutional investors have bought a total of 8,557,115 shares in the last 24 months. This purchase volume represents approximately $13.02M in transactions. Related Companies LYEL Institutional Ownership ALEC Institutional Ownership IPHA Institutional Ownership GLSI Institutional Ownership MGNX Institutional Ownership GNLX Institutional Ownership CKPT Institutional Ownership CRGX Institutional Ownership VXRT Institutional Ownership ADAP Institutional Ownership This page (NASDAQ:BRNS) was last updated on 2/22/2025 by MarketBeat.com Staff From Our PartnersElon’s “New Gold”MIT scientists just developed a brand-new metal… A metal that’s shaping up to be, not only the biggest brea...True Market Insiders | SponsoredCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | SponsoredWatch This Robotics Demo Before March 17thJeff Brown, the tech legend who picked shares of Nvidia in 2016 before they jumped by more than 22,000%... ...Brownstone Research | SponsoredThis Crypto Is Set to Explode in FebruaryIt's a groundbreaking opportunity that could be poised for extraordinary gains. The catalyst behind this su...Crypto 101 Media | SponsoredBuy this AI Stock Before Elon’s AnnouncementWith Trump back in office, xAI is primed to become the leader in generative AI, leaving competitors in the dus...InvestorPlace | SponsoredBuy NVDA Now? After weeks of volatility, did President Trump just turn Nvidia (NVDA) into a raging BUY? The beloved chip...Chaikin Analytics | SponsoredMarket down? Do this now.During Trump's first term, his tariffs sent gold prices soaring. Investors who acted early made a fortune. Now...Colonial Metals | SponsoredWhy Buffett and 100 members of Congress are Piling into this One InvestmentThis isn't just another investment. It might be the last retirement stock you'll ever need. But this win...Behind the Markets | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Barinthus Biotherapeutics plc Please log in to your account or sign up in order to add this asset to your watchlist. Share Barinthus Biotherapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
